96 related articles for article (PubMed ID: 9772305)
41. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
Odin L; Favrot M; Poujol D; Michot JP; Moingeon P; Tartaglia J; Puisieux I
Cancer Gene Ther; 2001 Feb; 8(2):87-98. PubMed ID: 11263530
[TBL] [Abstract][Full Text] [Related]
42. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
Geoerger B; Vassal G; Opolon P; Dirven CM; Morizet J; Laudani L; Grill J; Giaccone G; Vandertop WP; Gerritsen WR; van Beusechem VW
Cancer Res; 2004 Aug; 64(16):5753-9. PubMed ID: 15313916
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Branle F; Lefranc F; Camby I; Jeuken J; Geurts-Moespot A; Sprenger S; Sweep F; Kiss R; Salmon I
Cancer; 2002 Aug; 95(3):641-55. PubMed ID: 12209758
[TBL] [Abstract][Full Text] [Related]
44. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
45. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors.
Saleh M; Wiegmans A; Malone Q; Stylli SS; Kaye AH
J Natl Cancer Inst; 1999 Mar; 91(5):438-45. PubMed ID: 10070943
[TBL] [Abstract][Full Text] [Related]
46. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene.
Wei MX; Tamiya T; Chase M; Boviatsis EJ; Chang TK; Kowall NW; Hochberg FH; Waxman DJ; Breakefield XO; Chiocca EA
Hum Gene Ther; 1994 Aug; 5(8):969-78. PubMed ID: 7948146
[TBL] [Abstract][Full Text] [Related]
47. [Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection].
Zhu JX; Li ZM; Geng FY; Fu Q; Guo CJ; Xiao YL; Zhang ZT; Li G
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):709-12. PubMed ID: 21122390
[TBL] [Abstract][Full Text] [Related]
48. Tumor-preventive effects of the soluble p53 antigen on chemically-induced skin cancer in mice.
Ben-Hur H; Ben-Meir A; Hagay Z; Ben-Meir A; Berman V; Schwartsburd B; Gurevich P; Sandler B; Tendler Y; Zinder O; Zusman I
Anticancer Res; 1998; 18(6A):4237-41. PubMed ID: 9891473
[TBL] [Abstract][Full Text] [Related]
49. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
Harrington LE; Most Rv Rv; Whitton JL; Ahmed R
J Virol; 2002 Apr; 76(7):3329-37. PubMed ID: 11884558
[TBL] [Abstract][Full Text] [Related]
50. Adenovirus-mediated p53 gene therapy for human gliomas.
Lang FF; Yung WK; Sawaya R; Tofilon PJ
Neurosurgery; 1999 Nov; 45(5):1093-104. PubMed ID: 10549925
[TBL] [Abstract][Full Text] [Related]
51. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
[TBL] [Abstract][Full Text] [Related]
52. Effects of electrogenetherapy with p53wt combined with cisplatin on curvival of human tumor cell lines with different p53 status.
Cemazar M; Grosel A; Glavac D; Kotnik V; Skobrne M; Kranjc S; Mir LM; Andre F; Opolon P; Sersa G
DNA Cell Biol; 2003 Dec; 22(12):765-75. PubMed ID: 14683587
[TBL] [Abstract][Full Text] [Related]
53. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
54. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
Jiao H; Yang B; Guan F; Li J; Shan H; Song L; Hu X; Liang S; Du Y; Jiang C
Neurol Res; 2011 May; 33(4):405-14. PubMed ID: 21535940
[TBL] [Abstract][Full Text] [Related]
55. The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor.
Lidbury BA; Ramshaw IA; Sambhi SK
Cytokine; 1995 Feb; 7(2):157-64. PubMed ID: 7780035
[TBL] [Abstract][Full Text] [Related]
56. HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation.
Saydam O; Saydam N; Glauser DL; Pruschy M; Dinh-Van V; Hilbe M; Jacobs AH; Ackermann M; Fraefel C
Gene Ther; 2007 Aug; 14(15):1143-51. PubMed ID: 17495946
[TBL] [Abstract][Full Text] [Related]
57. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft.
Staba MJ; Mauceri HJ; Kufe DW; Hallahan DE; Weichselbaum RR
Gene Ther; 1998 Mar; 5(3):293-300. PubMed ID: 9614548
[TBL] [Abstract][Full Text] [Related]
58. Adenovirus-mediated p53 treatment enhances photodynamic antitumor response.
Lim DS; Bae SM; Kwak SY; Park EK; Kim JK; Han SJ; Oh CH; Lee CH; Lee WY; Ahn WS
Hum Gene Ther; 2006 Mar; 17(3):347-52. PubMed ID: 16544983
[TBL] [Abstract][Full Text] [Related]
59. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Yamini B; Yu X; Pytel P; Galanopoulos N; Rawlani V; Veerapong J; Bickenbach K; Weichselbaum RR
Clin Cancer Res; 2007 Oct; 13(20):6217-23. PubMed ID: 17947489
[TBL] [Abstract][Full Text] [Related]
60. [Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
Xu M; Lin C; Liang X
Zhonghua Yi Xue Za Zhi; 2000 Sep; 80(9):689-93. PubMed ID: 11798837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
